Recurrent CDC25C mutations drive malignant transformation in FPD/AML

Nat Commun. 2014 Aug 27;5:4770. doi: 10.1038/ncomms5770.


Familial platelet disorder (FPD) with predisposition to acute myelogenous leukaemia (AML) is characterized by platelet defects with a propensity for the development of haematological malignancies. Its molecular pathogenesis is poorly understood, except for the role of germline RUNX1 mutations. Here we show that CDC25C mutations are frequently found in FPD/AML patients (53%). Mutated CDC25C disrupts the G2/M checkpoint and promotes cell cycle progression even in the presence of DNA damage, suggesting a critical role for CDC25C in malignant transformation in FPD/AML. The predicted hierarchical architecture shows that CDC25C mutations define a founding pre-leukaemic clone, followed by stepwise acquisition of subclonal mutations that contribute to leukaemia progression. In three of seven individuals with CDC25C mutations, GATA2 is the target of subsequent mutation. Thus, CDC25C is a novel gene target identified in haematological malignancies. CDC25C is also useful as a clinical biomarker that predicts progression of FPD/AML in the early stage.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Platelet Disorders / complications
  • Blood Platelet Disorders / genetics*
  • Blood Platelet Disorders / pathology
  • Cell Cycle / genetics
  • Cell Line
  • Core Binding Factor Alpha 2 Subunit / genetics
  • DNA Damage
  • GATA2 Transcription Factor / genetics
  • Genetic Predisposition to Disease
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Leukemia, Myeloid, Acute / genetics*
  • Leukemia, Myeloid, Acute / pathology
  • Mice
  • Mutation*
  • Pedigree
  • Thrombocytopenia / genetics
  • cdc25 Phosphatases / genetics*
  • cdc25 Phosphatases / metabolism


  • Core Binding Factor Alpha 2 Subunit
  • GATA2 Transcription Factor
  • GATA2 protein, human
  • RUNX1 protein, human
  • CDC25C protein, human
  • cdc25 Phosphatases

Associated data

  • SRA/SRP043031